Why does reducing tumor embolization matter for target validation in bone metastasis models?

Tumor embolization from cell suspension injections can engraft in the lung and confound metastasis analysis, leading to false-positive signals. By implanting solid tumor grafts directly into bone, this method avoids pulmonary emboli and ensures that observed lung metastasis arises from true hematogenous spread. This increases confidence in target validation studies focused on bone-to-organ metastasis.

How does isolating the bone implantation variable improve discovery pipeline consistency?

Unlike intravascular or organ-specific injection models that introduce multiple variables, tibial graft implantation isolates bone engraftment as the primary event. This uniformity reduces variability in tumor take rates and growth kinetics across cohorts. As a result, downstream screening and efficacy studies benefit from more consistent baselines for compound comparison.

What quantitative measurements does longitudinal imaging enable in solid tumor graft models?

Weekly digital radiography, bioluminescence, and fluorescence imaging allow noninvasive tracking of tibial tumor growth and osteolysis progression. Caliper measurements at the implantation site provide complementary physical assessment of tumor burden. These outputs support quantitative endpoints for evaluating therapeutic effects on bone destruction and repair.

Why are replication requirements critical for cross-functional collaboration in bone metastasis modeling?

Reproducible engraftment, osteolysis, and metastasis across experiments ensure that findings are transferable between discovery, preclinical, and translational teams. Inconsistent models hinder alignment on go/no-go criteria and biomarker validation. This method’s high engraftment fidelity supports shared understanding and decision-making across functions.

What statistical analysis capabilities are needed before implementing solid tumor graft implantation in preclinical studies?

Teams must be able to analyze tumor growth curves, osteolysis rates, and metastasis incidence using appropriate statistical tests for longitudinal and endpoint data. Power calculations based on expected effect sizes and variability are essential for group sizing. The method’s reduced variability improves statistical power compared to injection-based models, but rigorous analysis remains required for valid conclusions.

Primer Kemik Tümörleri ve Kemik Metastazlarının Solid Tümör Grefti İmplantasyonu ile Modellenmesi

2.9K görüntüleme

14 kez atıf

06:53 dk

9 Eylül 2020

10.3791/61313-v

9 Eylül 2020

2.9K görüntüleme

Blake E. Hildreth III¹ , Charlotte Palmer² , Matthew J. Allen²

¹Department of Pathology and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, ²Surgical Discovery Centre, Department of Veterinary Medicine, University of Cambridge

Kemik metastazı modellerinde metastaz düzgün bir şekilde veya %100 insidansla gelişmez. Doğrudan intraosseöz tümör hücresi enjeksiyonu akciğerin embolizasyonu ile sonuçlanabilir. Primer kemik tümörlerini ve kemik metastazlarını, kemik içine solid tümör grefti implantasyonu kullanılarak modelleyen, tekrarlanabilir engraftman ve büyümeye yol açan tekniğimizi sunuyoruz.